To view this email as a web page, click here.
 
Top 5 pipeline drugs for 2018
Analysts predict the top 5 new pipeline drugs to treat HIV, diabetes, cancer, migraine head-aches and other conditions.
Read more
 
FDA okays short-acting follow-on insulin for diabetes
FDA approved the first short-acting insulin approved as a "follow-on" product.
Read more
 
New cancer biosimilar could net major sales
A new biosimilar to the cancer drug Herceptin, which raked in $2.5 billion in United States sales last year, is expected to produce blockbuster sales when it hits the market.
Read more
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.